The truth of the matter is that ETRM knew that they did have the resources to properly launch Vbloc, dangled "partnership discussions" for a year, and failed to deliver.
I added 4000 shares after hours. Just a modest but sustained improvement is HUGE. The health care savings would be tremendous. Many successful drugs are only incremental improvements, but reap billions in sales.
I bought 4K shares AH on Friday because of the news. The potential is incredible as stem cell therapy has only been tried in less than optimum cases and has worked. Getting off a respirator is huge and saves big money in hospital costs. As stem cells are implanted in better candidates the results should be even better. The potential worldwide market is huge!
The hatchet piece in San Francisco Business News conveniently ignores the fact that two major pharmas thought enough of XOMA compounds to do deals. It s just a matter of time before XOMA sells Gevo and/or is bought out.
The recent heavy options buying of Feb 18 $1.00 Calls virtually guaranteed that the manipulators would keep the Calls out of the money. Monday should see a nice rebound.
1) Their in-house programs;
2) Partnership with Novo Nordisk
3) Partnership with Novartis;
4) Holds $1,000,000 in Agenus (AGEN) stock
Sentiment: Strong Buy
(Today's bear raid creates a great entry point. No chance of a R/S as annual meeting filings do not mention and XOMA can easily transfer to NASDAQ Capital Market without being over one dollar).
"The current technical condition for XOMA is strong and the chart pattern suggests that upward momentum should continue.
The stock has outperformed the market over the last 50 trading days when compared to the S&P 500. The MACD-LT is confirming that the
intermediate-term trend is bullish. Upside momentum, as measured by the 9-day RSI indicator is very strong. Over the last 50 trading sessions, there
has been more volume on up days than on down days indicating that XOMA is under accumulation, which is a bullish condition. The stock is trading
above a rising 50-day moving average. This validates the strong technical condition for XOMA."